posted on 2023-03-30, 19:43authored byHayley D. McKeen, Christopher Byrne, Puthen V. Jithesh, Christopher Donley, Andrea Valentine, Anita Yakkundi, Martin O'Rourke, Charles Swanton, Helen O. McCarthy, David G. Hirst, Tracy Robson
Supplementary Figure 1 from FKBPL Regulates Estrogen Receptor Signaling and Determines Response to Endocrine Therapy
History
ARTICLE ABSTRACT
The HSP90 chaperone and immunophilin FKBPL is an estrogen-responsive gene that interacts with estogen receptor α (ERα) and regulates its levels. In this study, we explored the effects of FKBPL on breast cancer proliferation. Breast cancer cells stably overexpressing FKBPL became dependent on estrogen for their growth and were dramatically more sensitive to the antiestrogens tamoxifen and fulvestrant, whereas FKBPL knockdown reverses this phenotype. FKBPL knockdown also decreased the levels of the cell cycle inhibitor p21WAF1 and increased ERα phosphorylation on Ser118 in response to 17β-estradiol and tamoxifen. In support of the likelihood that these effects explained FKBPL-mediated cell growth inhibition and sensitivity to endocrine therapies, FKBPL expression was correlated with increased overall survival and distant metastasis-free survival in breast cancer patients. Our findings suggest that FKBPL may have prognostic value based on its impact on tumor proliferative capacity and sensitivity to endocrine therapies, which improve outcome. Cancer Res; 70(3); 1090–100